BEAM - Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors | Benzinga
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors.
"Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering dedication and drive to serve people living with life-threatening diseases, make her an ideal fit for Beam as we look to advance our pipeline of novel base editing therapeutics."
Ms. Shaw has more than 30 years of experience in the biopharmaceutical industry, and most recently served as chief executive officer of Kite, a Gilead company specializing in the development of immuno-oncology therapies until March 2023. Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines, the business within Lilly that comprises neuroscience and immunology. Before Lilly, she served as U.S. country head and president of Novartis Pharmaceutical Corporation, a global healthcare company, and in a prior role, as North American region head of Novartis Oncology. Ms. Shaw also held several leadership positions at Johnson & Johnson. She serves as a member of the board of directors of Avantor and is the co-founder of the More Moments More Memories Foundation, which helps people access oncology clinical trials for potentially life-saving treatment. She holds a bachelor's degree in business administration from Iowa State University and an ...